BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
BC Week In Review | Mar 30, 2018
Clinical News

Ablynx's CD126 nanobody misses in Phase II for lupus

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) said vobarilizumab (ALX-0061) missed the primary endpoint in the Phase II STEADY trial to treat systemic lupus erythematosus (SLE). The candidate is a nanobody against IL-6 receptor (CD126). STEADY enrolled 312...
BC Extra | Mar 26, 2018
Clinical News

Ablynx’s CD126 nanobody misses in Phase II for lupus

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) said vobarilizumab (ALX-0061) missed the primary endpoint in the Phase II STEADY trial to treat systemic lupus erythematosus (SLE). The candidate is a nanobody against IL-6 receptor (CD126). STEADY enrolled 312...
BioCentury | Feb 3, 2018
Strategy

Road to acquisition

Sanofi’s proposed acquisition of Ablynx N.V. puts considerable value not only on the Belgian biotech’s lead hematology asset caplacizumab, but also on its Nanobody platform, which fits the pharma’s R&D strategy of prioritizing development of...
BioCentury | Jan 13, 2018
Finance

Assessing Ablynx

While a group of investors in Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) don’t agree on what is fair value for the Belgian biotech, they do think a $2.8 billion offer from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) undervalues...
BC Week In Review | Jan 12, 2018
Company News

Ablynx rejects Novo's $2.8B acquisition proposal

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) made public news that its board rejected two unsolicited acquisition proposals from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). Ablynx said in a statement the latest proposal "fundamentally undervalues" the company. On Dec....
BC Extra | Jan 8, 2018
Company News

Ablynx rejects Novo's $2.8B acquisition proposal

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) gained €9.60 (45%) to €30.80 in Brussels and $12.71 (49%) to $38.62 in New York on Monday after making public news that its board rejected two unsolicited acquisition proposals from Novo...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Oct 24, 2016
Company News

Ablynx, AbbVie deal

AbbVie declined to exercise its option to license vobarilizumab (ALX-0061) from Ablynx to treat rheumatoid arthritis. AbbVie said that the safety and efficacy data for the subcutaneous nanobody against IL-6 receptor (CD126) “did not meet...
BC Extra | Oct 20, 2016
Company News

AbbVie declines Ablynx option in RA

Ablynx N.V. (Euronext:ABLX) fell EUR 1.41 (13%) to EUR 9.50 after AbbVie Inc. (NYSE:ABBV) declined to exercise its option to license vobarilizumab (ALX-0061) to treat rheumatoid arthritis. Ablynx said it is seeking a new partner...
Items per page:
1 - 10 of 17